Mirum raised its full‑year net product sales outlook to a $680‑$700 million range, reflecting a 46% jump in LIVMARLI revenue and expanding pipeline momentum. The higher target broadens upside potential while the company still posted a $‑0.80 EPS loss, keeping earnings pressure on investors.

Key Highlights

  • The next FDA milestones are expected to shape the company’s near‑term market positioning.
  • Investors are closely watching the regulatory timeline for potential catalytic impact.

- The next FDA milestones are expected to shape the company’s near‑term market positioning. - Investors are closely watching the regulatory timeline for potential catalytic impact.

Peers Moving on This News

  • Twist Bioscience Corp (TWST) little changed
  • Erasca Inc (ERAS) up 4.3%

Analysis based on the Form 8-K filed 5 August 2026.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.